BRPI0906522A2 - Sulfonamidas como antagonistas de orexina - Google Patents
Sulfonamidas como antagonistas de orexinaInfo
- Publication number
- BRPI0906522A2 BRPI0906522A2 BRPI0906522-9A BRPI0906522A BRPI0906522A2 BR PI0906522 A2 BRPI0906522 A2 BR PI0906522A2 BR PI0906522 A BRPI0906522 A BR PI0906522A BR PI0906522 A2 BRPI0906522 A2 BR PI0906522A2
- Authority
- BR
- Brazil
- Prior art keywords
- sulfonamides
- orexin antagonists
- orexin
- antagonists
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08150435 | 2008-01-21 | ||
PCT/EP2009/050272 WO2009092642A1 (en) | 2008-01-21 | 2009-01-12 | Sulfonamides as orexin antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0906522A2 true BRPI0906522A2 (pt) | 2015-07-14 |
Family
ID=40551459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0906522-9A BRPI0906522A2 (pt) | 2008-01-21 | 2009-01-12 | Sulfonamidas como antagonistas de orexina |
Country Status (12)
Country | Link |
---|---|
US (1) | US7932269B2 (pt) |
EP (1) | EP2245006B1 (pt) |
JP (1) | JP5220870B2 (pt) |
KR (1) | KR101178658B1 (pt) |
CN (1) | CN101918359B (pt) |
AT (1) | ATE511500T1 (pt) |
AU (1) | AU2009207750B2 (pt) |
BR (1) | BRPI0906522A2 (pt) |
CA (1) | CA2709050C (pt) |
ES (1) | ES2364806T3 (pt) |
IL (1) | IL206359A (pt) |
WO (1) | WO2009092642A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2962649A1 (fr) | 2010-07-19 | 2012-01-20 | Conservatoire Nat Arts Et Metiers | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide |
JP6346862B2 (ja) | 2012-02-07 | 2018-06-20 | エオラス セラピューティクス, インコーポレイテッド | オレキシンレセプターアンタゴニストとしての置換プロリン/ピペリジン |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
MX2016007661A (es) * | 2013-12-12 | 2017-01-06 | Univ Tsukuba | Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo. |
EP3180332B1 (en) | 2014-08-13 | 2021-10-27 | Eolas Therapeutics Inc. | Difluoropyrrolidines as orexin receptor modulators |
WO2016133160A1 (ja) * | 2015-02-19 | 2016-08-25 | 国立大学法人筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
WO2016199906A1 (ja) * | 2015-06-12 | 2016-12-15 | 国立大学法人筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
BR112018016446B1 (pt) | 2016-02-12 | 2024-02-06 | Eolas Therapeutics, Inc. | Composto de piperidina halo-substituída, composição farmacêutica compreendendo dito composto e uso terapêutico dos mesmos |
WO2018164192A1 (ja) * | 2017-03-08 | 2018-09-13 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
US11059780B2 (en) | 2017-03-08 | 2021-07-13 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL155333A0 (en) * | 2000-10-17 | 2003-11-23 | Applied Res | Sulfanilide derivatives for use in medicine, certain such new derivatives and their preparation |
BR0315115A (pt) * | 2002-10-11 | 2005-08-16 | Actelion Pharmaceuticals Ltd | Compostos, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios em que se requer um antagonista de receptores de orexina humana, processo para a fabricação de composições farmacêuticas, e, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos |
FR2874011B1 (fr) | 2004-08-03 | 2007-06-15 | Sanofi Synthelabo | Derives de sulfonamides, leur preparation et leur application en therapeutique |
CA2617324A1 (en) * | 2005-08-04 | 2007-02-15 | Merck & Co., Inc. | Aminoethane sulfonamide orexin receptor antagonists |
US8003654B2 (en) * | 2006-04-11 | 2011-08-23 | Actelion Pharmaceuticals Ltd. | N-glycinsulfonamide derivatives and uses as orexin receptor antagonists |
-
2009
- 2009-01-12 CN CN2009801026222A patent/CN101918359B/zh not_active Expired - Fee Related
- 2009-01-12 EP EP09703156A patent/EP2245006B1/en active Active
- 2009-01-12 BR BRPI0906522-9A patent/BRPI0906522A2/pt not_active Application Discontinuation
- 2009-01-12 ES ES09703156T patent/ES2364806T3/es active Active
- 2009-01-12 AT AT09703156T patent/ATE511500T1/de active
- 2009-01-12 CA CA2709050A patent/CA2709050C/en not_active Expired - Fee Related
- 2009-01-12 JP JP2010543459A patent/JP5220870B2/ja not_active Expired - Fee Related
- 2009-01-12 KR KR1020107016193A patent/KR101178658B1/ko not_active IP Right Cessation
- 2009-01-12 WO PCT/EP2009/050272 patent/WO2009092642A1/en active Application Filing
- 2009-01-12 AU AU2009207750A patent/AU2009207750B2/en not_active Ceased
- 2009-01-14 US US12/353,506 patent/US7932269B2/en not_active Expired - Fee Related
-
2010
- 2010-06-14 IL IL206359A patent/IL206359A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL206359A (en) | 2014-06-30 |
ES2364806T3 (es) | 2011-09-14 |
JP5220870B2 (ja) | 2013-06-26 |
JP2011510037A (ja) | 2011-03-31 |
EP2245006A1 (en) | 2010-11-03 |
KR20100092979A (ko) | 2010-08-23 |
EP2245006B1 (en) | 2011-06-01 |
AU2009207750A1 (en) | 2009-07-30 |
CN101918359A (zh) | 2010-12-15 |
AU2009207750B2 (en) | 2013-03-14 |
CA2709050A1 (en) | 2009-07-30 |
CA2709050C (en) | 2016-06-14 |
US7932269B2 (en) | 2011-04-26 |
WO2009092642A1 (en) | 2009-07-30 |
CN101918359B (zh) | 2013-02-27 |
US20090186920A1 (en) | 2009-07-23 |
ATE511500T1 (de) | 2011-06-15 |
IL206359A0 (en) | 2010-12-30 |
KR101178658B1 (ko) | 2012-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0906522A2 (pt) | Sulfonamidas como antagonistas de orexina | |
CY1119515T1 (el) | Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης | |
CY1119218T1 (el) | Αναστολεις διυδροπυριδοφθαλαζινονης της πολυμερασης της πολυαδενοσφωσφορικης ριβοζης (parp) | |
DE602007012072D1 (de) | Orantagonisten | |
ECSP088210A (es) | Bencimidazoles sustituidos y métodos de preparación | |
EA201270149A1 (ru) | Ингибиторы bace | |
EA201170884A1 (ru) | Производные пиперидина, пригодные в качестве антагонистов орексина | |
ATE500250T1 (de) | Azetidinverbindungen als orexin-rezeptor- antagonisten | |
MA32939B1 (fr) | Composes organiques | |
ECSP11010885A (es) | Heteroarilos sustituidos | |
CO6311079A2 (es) | Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer | |
EA200970666A1 (ru) | Трициклические соединения, композиции и способы | |
BRPI0813966A8 (pt) | Usos de mdl-1 | |
UY32384A (es) | Nuevas bencenosulfonamidas como bloqueadores de canales de calcio | |
EA201071234A1 (ru) | Производные изохинолинона в качестве nk3 антагонистов | |
UA106873C2 (uk) | Сполуки заміщених діазепанів як антагоністи орексинових рецепторів | |
TW200800958A (en) | N-substituted-azacyclylamines as histamine-3 antagonists | |
BRPI0916657A2 (pt) | pirrolidin-3-ilmetil-amina como antagonistas de orexina | |
CU20100115A7 (es) | Intermedios útiles para la preparación de derivados de carboxamida como antagonistas del receptor muscarínico | |
BRPI0814772A2 (pt) | Indazóis substituídos por 5-piridinona | |
CO6382123A2 (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
EA201290558A1 (ru) | Агонисты mglu2 | |
EA201270256A1 (ru) | Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида | |
EA201270255A1 (ru) | 5-фтор-2-оксопиримидин-1(2h)-карбоксилатные производные | |
EA201170585A1 (ru) | Производные изохинолинона в качестве антагонистов nk3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |